Proteo announced that the FDA has granted orphan drug designation to Elafin for the treatment of pulmonary arterial hypertension. Elafin is a copy of a naturally occurring human anti-inflammatory substance. It is a natural antagonist of the tissue destroying proteases that participate in the inflammatory mechanism.
The tolerability of intravenously administered recombinant Elafin has been demonstrated in a Phase 1 clinical trial.
For more information visit www.proteo.de.